Opinion

Hims & Hers recently made a move that looks bold on the surface—but may turn out to be a big mistake.

The company announced it plans to sell a $49-a-month weight-loss pill meant to compete with popular injectable drugs like Ozempic and Wegovy. The problem? Pills like this usually don’t work as well as injections, and experts have known that for years.

Even the companies that make these drugs, like Novo Nordisk and Eli Lilly, have shown in their own studies that pills lead to much less weight loss than shots. That’s when people follow instructions perfectly. In real life, results are usually worse.

Why? Because most people struggle to take pills exactly as directed—every day, at the same time, and often on an empty stomach. Doctors see this all the time. It’s one of the most common reasons people end up in the hospital with long-term health problems. Missing doses makes the drug far less effective.

Shots, even though people don’t love needles, are often easier to stick with. You take them once a week and you’re done.

Instead of focusing on what works best for patients, Hims & Hers seems to have chased attention and quick profits. The announcement came right before major advertising season, raising questions about whether this was more about headlines than health.

If the goal was to boost the company’s stock, it didn’t work. Shares dropped after the news. Around the same time, the head of the FDA publicly signaled tougher enforcement that could hurt Hims & Hers—and possibly other companies that help provide lower-cost versions of these drugs.

That’s where things get risky.

Millions of Americans depend on custom-made versions of weight-loss shots because brand-name drugs are often too expensive or hard to get. Many trusted pharmacies legally provide these options. But now, access for these patients could be threatened because one company pushed too far, too fast.

If the government decides to step in, it should focus only on the company that caused the problem—not punish patients or responsible pharmacies that are trying to help people get healthier.

There’s also a much bigger issue ahead.

In just a few months, very cheap versions of these weight-loss drugs are expected to be sold in China and India. If those countries make it easier and cheaper for people to treat obesity and diabetes, they could save massive amounts on healthcare. Meanwhile, the U.S. risks falling behind by fighting over rules and publicity stunts instead of focusing on access and results.

These drugs are one of the biggest health breakthroughs in decades. They can help prevent diabetes, heart disease, and other serious illnesses. But careless business decisions could slow everything down.

Sometimes, the smartest move is not making noise—but doing what actually works. Hims & Hers may have forgotten that, and the consequences could affect far more than just one company